Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Paraosmia
Interventions: Platelet-rich Plasma (PRP), Saline; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Type 2 Diabetes Mellitus
Interventions: RO7795081, Semaglutide, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 21
States / cities: Tucson, Arizona • Lake Forest, California • Rancho Cucamonga, California + 18 more

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate, Lisdexamfetamine, Atomoxetine, Amphetamine, Dextroamphetamine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: Not listed
Enrollment: 430,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
Interventions: Avelumab, Axitinib, Palbociclib; Drug
Lead sponsor: Worldwide Innovative Network Association; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: La Jolla, California • Sioux Falls, South Dakota

Conditions: Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
Interventions: Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Hattiesburg, Mississippi

Conditions: Solid Tumors, Advanced Malignancies, Metastatic Cancer
Interventions: Azacitidine, Pembrolizumab, Epacadostat, INCB057643, INCB059872; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: Duarte, California • La Jolla, California • Chicago, Illinois + 4 more

Conditions: Muscle Mass and Strength
Interventions: Resistance Exercise Program, Nutrition and Exercise Counseling; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Cancer, Epithelial Tumor
Interventions: NG-641 in combination with Nivolumab; Biological
Lead sponsor: Akamis Bio; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Fullerton, California • Santa Monica, California • Celebration, Florida + 1 more

Conditions: Primary Mitochondrial Myopathy
Interventions: elamipretide, placebo comparator, elamipretide open label treatment; Combination Product
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 13
States / cities: La Jolla, California • Palo Alto, California • Aurora, Colorado + 9 more

Conditions: Solid Tumor
Interventions: STP707; Drug
Lead sponsor: Sirnaomics; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 6 more

Conditions: Childhood Obesity
Interventions: Social Support, Nutrition Session, Physical Activity Session; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 9 Years to 11 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Healthy Participants
Interventions: BLU-808, Placebo, Midazolam; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Metastatic Uveal Melanoma
Interventions: Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Adolescent Behavior
Interventions: Mighty Girls, Game Girls; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 11 Years to 14 Years · Female only
Enrollment: 552 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Autism
Interventions: Memantine - Extended Release (ER), Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 17
States / cities: Phoenix, Arizona • Sacramento, California • San Francisco, California + 14 more

Conditions: Infertility
Interventions: Physician phone call; Behavioral
Lead sponsor: Boston IVF; Other
Eligibility: 18 Years to 43 Years · Female only
Enrollment: 231 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, Matching placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Months to 5 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 33
States / cities: Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more

Conditions: Neoplasms
Interventions: RO6895882; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Metabolic Dysfunction-associated Steatohepatitis
Interventions: Efimosfermin alfa, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 33
States / cities: Little Rock, Arkansas • Arcadia, California • Arroyo Grande, California + 27 more

Conditions: Healthy Participants
Interventions: PF-06700841 IR, PF-06700841 MR1, PF-06700841 MR2, PF-06700841 MR3, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Coral Gables, Florida • Miami, Florida

Conditions: Traumatic Brain Injury
Interventions: Cognitive/Neuropsychological Testing, Vestibular/Ocular-Motor Testing, Sleep Evaluation, MRI, High-Resolution, Health & Physical Exam, Physical Function, Blood Testing and Biomarker Analysis, Applanation Tonometry, PET brain imaging, [C-11]6-OH-BTA-1, [F-18]AV-1451; Diagnostic Test · Drug
Lead sponsor: David Okonkwo, MD, PhD; Other
Eligibility: 29 Years to 59 Years · Male only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hepatitis C
Interventions: Placebo, TG4040; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 2
States / cities: St Louis, Missouri • Cincinnati, Ohio

Conditions: Intervention 1: Resilience and Coping for Healthcare Group, Intervention 2: Resilience and Coping for Healthcare Plus Additional Services, Waitlist Control Group
Interventions: RCHC+, Waitlist control; Behavioral · Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glaucoma
Interventions: Prostaglandin Analogue -Containing IOP-Lowering Therapy, Beta Blocker, Brillouin Microscopy; Drug · Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Randomized Clinical Trial of Intranasal Injection of Platelet-Rich Plasma for Treatment of Parosmia

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

Survival Prolongation by Rationale Innovative Genomics

A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

Effects of Resistance Exercise Among TGD Individuals Initiating Estrogen-Based Gender-Affirming Hormone Therapy

Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours

A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

Healthy Families: Transforming Care for Obese Children at NYU Lutheran Family Health Centers

Study of BLU-808 in Healthy Adult Participants

Tebentafusp-tebn With LDT in Metastatic UM

JUEGA: A Fun Study for Hispanic/Latino Adolescent Girls

Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism

Impact of Physician Contact on Patient Anxiety During the Waiting Period After Embryo Transfer

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors

A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations

University of Pittsburgh Brain Health Initiative

TG4040 in Patients With Chronic HCV

Health and Wellness in Healthcare Providers Post-disaster

Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy